In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease.
In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease.
复制标题
作者：
由于肿瘤坏死因子（TNF）的抗体通过与膜结合TNF（mTNF）结合来抑制克罗恩病的免疫反应，我们创建了一种荧光抗体用于这种疾病的分子mTNF成像。在25例克罗恩病患者中给予局部抗体导致在共聚焦激光显微内镜检查期间检测到肠道mTNF+免疫细胞。与低mTNF+细胞量的患者（15%）相比，高mTNF+细胞量的患者在随后的抗TNF治疗后第12周显示出显著更高的短期应答率（92%）。在1年的随访期内，前一组患者的临床反应持续存在，并与随访内窥镜检查中观察到的粘膜愈合相关。这些数据表明，荧光抗体的分子成像有可能预测生物治疗的治疗反应，并可用于克罗恩病和自身免疫性或炎症性疾病的个性化医疗。
As antibodies to tumor necrosis factor (TNF) suppress immune responses in Crohn’s disease by binding to membrane-bound TNF (mTNF), we created a fluorescent antibody for molecular mTNF imaging in this disease. Topical antibody administration in 25 patients with Crohn’s disease led to detection of intestinal mTNF+ immune cells during confocal laser endomicroscopy. Patients with high numbers of mTNF+ cells showed significantly higher short-term response rates (92%) at week 12 upon subsequent anti-TNF therapy as compared to patients with low amounts of mTNF+ cells (15%). This clinical response in the former patients was sustained over a follow-up period of 1 year and was associated with mucosal healing observed in follow-up endoscopy. These data indicate that molecular imaging with fluorescent antibodies has the potential to predict therapeutic responses to biological treatment and can be used for personalized medicine in Crohn’s disease and autoimmune or inflammatory disorders.
登录
查看更多内容
影响因子：
11.2
作者：
Medarova Z;Rashkovetsky L;Pantazopoulos P;Moore A
通讯作者：
Moore A
影响因子：
29.4
作者：
Atreya, Raja;Zimmer, Michael;Neurath, Markus F.
通讯作者：
Neurath, Markus F.
影响因子：
29.4
作者：
Hanauer, SB;Sandborn, WJ;Pollack, P
通讯作者：
Pollack, P
影响因子：
82.9
作者：
通讯作者：
--
影响因子：
8.6
作者：
Kaymakcalan, Zehra;Sakorafas, Paul;Sasso, Eric H.
通讯作者：
Sasso, Eric H.